Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

Trial Profile

Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Natural killer cell therapy (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors NantKwest
  • Most Recent Events

    • 27 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 27 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 Dec 2016 Status changed from active, no longer recruiting to completed, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top